---

---

symbols : AZN   

save search

---

Precision Medicine Market size to grow by USD 54.07 billion from 2022 to 2027, The growing prevalence of chronic diseases to boost market growth - Technavio
Published: 2023-06-06 (Crawled : 04:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| -3.37% | O: 1.18% H: 0.37% C: -0.99%
NVSEF | News | $96.0 6.88% 52K |

Health Technology

| 17.37% | O: 1.88% H: 0.0% C: -1.15%
TMO | News | $577.39 0.49% 0.0% 2M |

Health Technology

| 9.04% | O: 0.66% H: 0.23% C: -1.1%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| -0.51% | O: 0.91% H: 0.1% C: -0.61%
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| 23.88% | O: 0.45% H: 0.05% C: -1.48%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -7.73% | O: 0.94% H: 0.27% C: 0.02%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| -3.21% | O: 0.79% H: 0.27% C: -0.52%
AMGN | News | $273.085 -0.17% -0.17% 2.5M |

Health Technology

| 23.28% | O: 0.54% H: 0.04% C: -0.83%
growing growth market

---

ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing Advanced Solid Tumors
Published: 2023-06-05 (Crawled : 19:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| -2.4% | O: 0.39% H: 0.78% C: 0.45%
enhertu her2 tumors

---

Datopotamab Deruxtecan Combinations Showed Encouraging Tumor Responses in Patients with Advanced Non-Small Cell Lung Cancer in TROPION-Lung02 Phase 1b trial
Published: 2023-06-05 (Crawled : 17:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| -2.4% | O: 0.39% H: 0.78% C: 0.45%
lung cancer cell tumor trial

---

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumors
Published: 2023-06-05 (Crawled : 17:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| -2.4% | O: 0.39% H: 0.78% C: 0.45%
enhertu tumors

---

Peptide Therapeutics Global Market Report 2023: Increase in the Prevalence of Chronic Diseases Drives Growth
Published: 2023-06-01 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -7.07% | O: -0.56% H: 0.0% C: 0.0%
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| -5.01% | O: -0.74% H: 1.4% C: 0.35%
NVSEF | News | $96.0 6.88% 52K |

Health Technology

| 18.53% | O: 0.99% H: 0.0% C: 0.0%
TAK | News | $13.23 -1.12% 0.0% 920K |

Health Technology

| -16.02% | O: 1.32% H: 0.31% C: 0.12%
PFE | News 4 | $26.27 -0.19% -0.15% 23M |

Health Technology

| -30.77% | O: 0.6% H: 1.07% C: 0.29%
NVO | News | $126.16 -1.93% -0.23% 3.1M |

Health Technology

| -18.57% | O: -1.84% H: 1.62% C: 1.33%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| 1.8% | O: 1.03% H: 0.84% C: 0.82%
BMY | $48.86 -0.27% -0.02% 16M |

Health Technology

| -24.26% | O: 0.37% H: 1.34% C: 1.14%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -6.33% | O: 1.05% H: 0.0% C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| -2.73% | O: 0.11% H: 0.69% C: -0.45%
report global therapeutics growth market

---

Kiyatec and AstraZeneca Announce a Multifaceted Research Agreement to Generate Novel Preclinical Data Using Kiyatec’s 3D Spheroid Screening Platform, KIYA-PredictTM
Published: 2023-05-30 (Crawled : 13:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| -2.3% | O: 0.44% H: 0.03% C: -1.94%
research preclinical agreement

---

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Published: 2023-05-30 (Crawled : 13:00) - biospace.com/
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| -2.94% | O: -0.34% H: 0.21% C: -2.03%
GNPX | $2.31 6.77% 20K |

Health Technology

| 159.55% | O: 1.12% H: 2.16% C: -10.76%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| -2.3% | O: 0.44% H: 0.03% C: -1.94%
reqorsa lung approval review cancer cell expansion trial

---

Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting
Published: 2023-05-25 (Crawled : 21:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| -3.41% | O: -0.47% H: 0.0% C: -0.02%
GNPX | $2.31 6.77% 20K |

Health Technology

| 171.76% | O: 3.65% H: 7.04% C: 1.02%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| -1.31% | O: 1.06% H: 0.48% C: -0.04%
reqorsa lung asco positive cancer cell meeting trial therapy

---

Head and Neck Cancer Market Worth US$ 5.0 billion by 2032, with a CAGR of 12.9% during the Forecast Period
Published: 2023-05-24 (Crawled : 10:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| -5.16% | O: -1.2% H: 0.0% C: -1.65%
LLY | News | $732.2 -1.81% 0.18% 2.1M |

Health Technology

| 74.63% | O: 0.19% H: 1.17% C: 0.42%
BMY | $48.86 -0.27% -0.02% 16M |

Health Technology

| -26.36% | O: 0.11% H: 0.14% C: -1.7%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -13.41% | O: 0.14% H: 0.1% C: -0.83%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| -4.35% | O: -1.56% H: 0.25% C: -0.71%
cancer market

---

Sustained Release Coating Market size to grow by USD 207.64 million from 2022 to 2027, North America to account for 43% of the market growth - Technavio
Published: 2023-05-24 (Crawled : 03:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| -5.16% | O: -1.2% H: 0.0% C: -1.65%
NVSEF | News | $96.0 6.88% 52K |

Health Technology

| 15.77% | O: 0.74% H: 0.0% C: -1.75%
VTRS | News A | $11.55 1.67% 1.65% 7.2M |

Health Technology

| 22.94% | O: -0.32% H: 0.0% C: -1.95%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| -1.39% | O: -0.06% H: 0.04% C: -0.16%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| -4.35% | O: -1.56% H: 0.25% C: -0.71%
america growth market

---

Injection Pen Market Size is Projected To Reach USD 80,511.51 Million By 2031, Growing at a CAGR of 7.8% | Valuates Reports
Published: 2023-05-23 (Crawled : 14:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| -5.14% | O: 0.7% H: 1.22% C: -0.67%
NONOF | $128.38 0.31% 97K |

Health Technology

| -24.48% | O: 0.01% H: 0.0% C: -3.5%
LLY | News | $732.2 -1.81% 0.18% 2.1M |

Health Technology

| 70.29% | O: -0.25% H: 0.69% C: -2.24%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -13.41% | O: -0.01% H: 0.0% C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| -4.84% | O: 0.97% H: 0.0% C: -1.46%
reach growing injection market

---

Global Protein Therapeutics Market Report 2023: Development of Plasma Derived Therapies Drives Growth
Published: 2023-05-23 (Crawled : 02:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| -5.14% | O: 0.7% H: 1.22% C: -0.67%
NVO | News | $126.16 -1.93% -0.23% 3.1M |

Health Technology

| -24.56% | O: -1.39% H: 0.06% C: -2.77%
JNJ | News | $148.53 -0.69% -0.14% 9.6M |

Health Technology

| -4.6% | O: 0.15% H: 0.74% C: -0.18%
LLY | News | $732.2 -1.81% 0.18% 2.1M |

Health Technology

| 70.29% | O: -0.25% H: 0.69% C: -2.24%
ABT | News | $106.89 -0.65% -0.22% 5.1M |

Health Technology

| -0.61% | O: -0.88% H: 0.17% C: -1.45%
ORMP A | $2.375 1.06% 1.05% 41K |

Health Technology

| -46.95% | O: 0.9% H: 10.29% C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| -4.84% | O: 0.97% H: 0.0% C: -1.46%
report global protein therapeutics growth market

---

Autoimmune Drugs Market size to grow by USD 29,314.5 million between 2022 and 2027; AbbVie Inc., and AdvaCare Pharma among others, identified as key vendors - Technavio
Published: 2023-05-19 (Crawled : 00:20) - prnewswire.com
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| Email alert Add to watchlist
GLAXF | News | $19.54 -14.18% 2.6K |

Health Technology

| Email alert Add to watchlist
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| Email alert Add to watchlist
GSK | News | $40.86 -0.92% -0.15% 1.7M |

Health Technology

| Email alert Add to watchlist
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| Email alert Add to watchlist
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| Email alert Add to watchlist
TEVJF | News | $12.37 -24.22% 380 |

Health Technology

| Email alert Add to watchlist
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| Email alert Add to watchlist
AMGN | News | $273.085 -0.17% -0.17% 2.5M |

Health Technology

| Email alert Add to watchlist
pharma abbvie market

---

Revvity Announces New License Agreement for Next-Generation Base Editing Technology
Published: 2023-05-18 (Crawled : 12:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| -5.15% | O: 0.28% H: 0.31% C: -0.93%
license technology agreement

---

Over-The-Counter Drug Market size to grow by USD 58.54 billion from 2022 to 2027, Abbott Laboratories and Achelios Therapeutics Inc. emerge as key contributors to market growth - Technavio
Published: 2023-05-17 (Crawled : 21:00) - prnewswire.com
RBGPF | News | $52.06 6.46% 4.8K |

Consumer Non-Durables

| -35.23% | O: -0.55% H: 2.89% C: -0.35%
GLAXF | News | $19.54 -14.18% 2.6K |

Health Technology

| 5.62% | O: -4.32% H: 1.69% C: 1.69%
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| -4.69% | O: 1.82% H: 0.0% C: -2.3%
RBGLY | News | $10.59 -2.05% 850K |

Manufacturing

| -34.21% | O: -0.18% H: 0.24% C: -0.08%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| -2.33% | O: -0.49% H: 0.42% C: -0.37%
GSK | News | $40.86 -0.92% -0.15% 1.7M |

Health Technology

| 14.11% | O: -1.55% H: 0.11% C: -1.04%
ABT | News | $106.89 -0.65% -0.22% 5.1M |

Health Technology

| -1.13% | O: -0.08% H: 0.1% C: -0.24%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -12.6% | O: 0.16% H: 0.0% C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| -5.15% | O: 0.28% H: 0.31% C: -0.93%
drug therapeutics growth market

---

Global Glioblastoma Multiforme (GBM) Treatment Market Report 2023: Increasing Prevalence of Brain Disorders is Expected to Propel Growth
Published: 2023-05-17 (Crawled : 01:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| -7.21% | O: -1.32% H: 0.92% C: -1.34%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| -3.84% | O: -0.51% H: 0.0% C: -1.05%
FUSN | $21.4 -0.09% -0.09% 270K |

Health Technology

| 369.74% | O: -1.54% H: 1.34% C: -2.67%
DFFN 4 | $6.6 11.68% -34.32% 350K |

Health Technology

| 14.59% | O: -0.25% H: 0.0% C: -0.78%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| -5.88% | O: 0.07% H: 0.03% C: -0.84%
AMGN | News | $273.085 -0.17% -0.17% 2.5M |

Health Technology

| 20.04% | O: -0.82% H: 0.03% C: -0.44%
propel report expected treatment global growth glioblastoma market

---

Global Blood Cancer Drugs Market Report 2023: Increasing Prevalence of Blood Cancer Cases Drives Growth
Published: 2023-05-16 (Crawled : 22:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| -7.21% | O: -1.32% H: 0.92% C: -1.34%
JNJ | News | $148.53 -0.69% -0.14% 9.6M |

Health Technology

| -6.08% | O: 0.28% H: 0.17% C: -0.5%
BMY | $48.86 -0.27% -0.02% 16M |

Health Technology

| -26.9% | O: 0.06% H: 0.43% C: -0.79%
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| 18.32% | O: -0.19% H: 0.35% C: 0.23%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| -5.88% | O: 0.07% H: 0.03% C: -0.84%
AMGN | News | $273.085 -0.17% -0.17% 2.5M |

Health Technology

| 20.04% | O: -0.82% H: 0.03% C: -0.44%
report cancer blood global growth market

---

Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
Published: 2023-05-15 (Crawled : 20:00) - globenewswire.com
DERM | $3.425 -3.25% -3.36% 60K |

| 144.14% | O: 2.41% H: 8.42% C: 1.01%
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| -6.12% | O: 1.17% H: 0.0% C: 0.0%
MBIO | $0.35 -2.7% -2.77% 120K |

Health Technology

| -91.72% | O: 0.0% H: 1.24% C: -0.23%
FBIO | $1.785 -1.38% -1.4% 120K |

Health Technology

| 156.01% | O: 4.67% H: 1.34% C: -10.55%
CKPT | $1.44 0.35% 0.35% 180K |

Health Technology

| -49.12% | O: 1.41% H: 2.79% C: -2.79%
ATXI | $0.0949 -29.18% -41.2% 12M |

Health Technology

| -87.85% | O: 0.0% H: 0.0% C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| -5.52% | O: 0.44% H: 0.44% C: -0.05%
biotech financial results

---

Zollinger-Ellison Syndrome (Gastrinoma) Clinical Trial Analysis Report 2023: Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries
Published: 2023-05-12 (Crawled : 00:20) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| Email alert Add to watchlist
NVSEF | News | $96.0 6.88% 52K |

Health Technology

| Email alert Add to watchlist
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| Email alert Add to watchlist
TEVJF | News | $12.37 -24.22% 380 |

Health Technology

| Email alert Add to watchlist
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| Email alert Add to watchlist
report trial

---

LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate
Published: 2023-05-12 (Crawled : 21:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| -5.19% | O: 0.29% H: 0.81% C: -0.29%
lm-305 drug antibody license global agreement

---

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M |

Consumer Services

BOF | $1.99 70.09% 41.21% 110M |

ILAG | $0.51 6.03% 40.62% 1.7M |

LICN | $0.941 68.04% 40.49% 15M |

AMST | $3.31 65.5% 39.58% 70M |

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M |

Technology Services

WIMI | $1.15 58.53% 36.92% 19M |

Technology Services

AIH | $0.45 12.5% 30.92% 320K |

Health Services

MULN | News | $3.78 38.46% 27.78% 13M |

Information

RILY | $29.86 37.48% 27.26% 12M |

Finance

---

Your saved searches

---